ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) VP Meredith Cook Sells 400 Shares

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) VP Meredith Cook sold 400 shares of ANI Pharmaceuticals stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $63.33, for a total value of $25,332.00. Following the completion of the sale, the vice president now directly owns 80,545 shares in the company, valued at approximately $5,100,914.85. The trade was a 0.49 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Meredith Cook also recently made the following trade(s):

• On Thursday, February 13th, Meredith Cook sold 400 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $59.54, for a total value of $23,816.00.
• On Monday, January 13th, Meredith Cook sold 400 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $53.92, for a total value of $21,568.00.

ANI Pharmaceuticals Price Performance

Shares of ANIP stock opened at $62.49 on Friday. ANI Pharmaceuticals, Inc. has a twelve month low of $52.50 and a twelve month high of $70.81. The stock has a market capitalization of $1.36 billion, a price-to-earnings ratio of -113.62 and a beta of 0.62. The stock has a fifty day simple moving average of $58.26 and a two-hundred day simple moving average of $58.13. The company has a current ratio of 2.74, a quick ratio of 1.97 and a debt-to-equity ratio of 1.52.

Analyst Ratings Changes

A number of equities analysts have recently commented on ANIP shares. StockNews.com upgraded ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday. JPMorgan Chase & Co. started coverage on ANI Pharmaceuticals in a report on Wednesday. They issued an “overweight” rating and a $85.00 target price for the company. Jefferies Financial Group assumed coverage on ANI Pharmaceuticals in a report on Friday. They issued a “buy” rating and a $80.00 target price for the company. Leerink Partners assumed coverage on ANI Pharmaceuticals in a report on Wednesday, December 11th. They set an “outperform” rating and a $80.00 price objective for the company. Finally, Guggenheim boosted their price objective on ANI Pharmaceuticals from $84.00 to $86.00 and gave the company a “buy” rating in a report on Wednesday, March 5th. Two investment analysts have rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $79.78.

Institutional Investors Weigh In On ANI Pharmaceuticals

Several hedge funds have recently made changes to their positions in the company. Thrivent Financial for Lutherans lifted its holdings in shares of ANI Pharmaceuticals by 2.3% in the 3rd quarter. Thrivent Financial for Lutherans now owns 13,028 shares of the specialty pharmaceutical company’s stock worth $777,000 after buying an additional 299 shares during the period. Exchange Traded Concepts LLC lifted its holdings in shares of ANI Pharmaceuticals by 2.6% in the 4th quarter. Exchange Traded Concepts LLC now owns 12,366 shares of the specialty pharmaceutical company’s stock worth $684,000 after buying an additional 310 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of ANI Pharmaceuticals by 3.6% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 10,523 shares of the specialty pharmaceutical company’s stock worth $582,000 after buying an additional 364 shares during the period. China Universal Asset Management Co. Ltd. lifted its holdings in shares of ANI Pharmaceuticals by 10.2% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 4,457 shares of the specialty pharmaceutical company’s stock worth $246,000 after buying an additional 412 shares during the period. Finally, Natixis Advisors LLC raised its position in shares of ANI Pharmaceuticals by 2.3% in the 4th quarter. Natixis Advisors LLC now owns 18,601 shares of the specialty pharmaceutical company’s stock worth $1,028,000 after acquiring an additional 417 shares in the last quarter. 76.05% of the stock is currently owned by hedge funds and other institutional investors.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.